Interleukin-17A-induced production of acute serum amyloid A by keratinocytes contributes to psoriasis pathogenesis

PLoS One. 2017 Jul 14;12(7):e0181486. doi: 10.1371/journal.pone.0181486. eCollection 2017.

Abstract

Background: Acute-serum Amyloid A (A-SAA), one of the major acute-phase proteins, is mainly produced in the liver but extra-hepatic synthesis involving the skin has been reported. Its expression is regulated by the transcription factors NF-κB, C/EBPβ, STAT3 activated by proinflammatory cytokines.

Objectives: We investigated A-SAA synthesis by resting and cytokine-activated Normal Human Epidermal Keratinocytes (NHEK), and their inflammatory response to A-SAA stimulation. A-SAA expression was also studied in mouse skin and liver in a model mimicking psoriasis and in the skin and sera of psoriatic and atopic dermatitis (AD) patients.

Methods: NHEK were stimulated by A-SAA or the cytokines IL-1α, IL-17A, IL-22, OSM, TNF-α alone or in combination, previously reported to reproduce features of psoriasis. Murine skins were treated by imiquimod cream. Human skins and sera were obtained from patients with psoriasis and AD. A-SAA mRNA was quantified by RT qPCR. A-SAA proteins were dosed by ELISA or immunonephelemetry assay.

Results: IL-1α, TNF-α and mainly IL-17A induced A-SAA expression by NHEK. A-SAA induced its own production and the synthesis of hBD2 and CCL20, both ligands for CCR6, a chemokine receptor involved in the trafficking of Th17 lymphocytes. A-SAA expression was increased in skins and livers from imiquimod-treated mice and in patient skins with psoriasis, but not significantly in those with AD. Correlations between A-SAA and psoriasis severity and duration were observed.

Conclusion: Keratinocytes could contribute to psoriasis pathogenesis via A-SAA production, maintaining a cutaneous inflammatory environment, activating innate immunity and Th17 lymphocyte recruitment.

MeSH terms

  • Adult
  • Aged
  • Aminoquinolines / pharmacology
  • Animals
  • Cells, Cultured
  • Chemokine CCL20 / metabolism
  • Chemokine CCL20 / pharmacology
  • Cytokines / genetics
  • Cytokines / metabolism
  • Dermatitis, Atopic / metabolism
  • Dermatitis, Atopic / pathology*
  • Disease Models, Animal
  • Female
  • Humans
  • Imiquimod
  • Interleukin-17 / genetics
  • Interleukin-17 / metabolism
  • Interleukin-17 / pharmacology*
  • Keratinocytes / cytology
  • Keratinocytes / drug effects
  • Keratinocytes / metabolism
  • Liver / drug effects
  • Liver / metabolism
  • Male
  • Mice
  • Mice, Inbred C57BL
  • Middle Aged
  • Psoriasis / metabolism
  • Psoriasis / pathology*
  • Receptors, CCR6 / metabolism
  • Recombinant Proteins / biosynthesis
  • Recombinant Proteins / isolation & purification
  • Recombinant Proteins / pharmacology
  • Serum Amyloid A Protein / analysis
  • Serum Amyloid A Protein / genetics
  • Serum Amyloid A Protein / metabolism*
  • Skin / drug effects*
  • Skin / metabolism
  • Th17 Cells / cytology
  • Th17 Cells / metabolism
  • Up-Regulation / drug effects*

Substances

  • Aminoquinolines
  • Chemokine CCL20
  • Cytokines
  • Interleukin-17
  • Receptors, CCR6
  • Recombinant Proteins
  • Serum Amyloid A Protein
  • Imiquimod

Grants and funding

The authors received no specific funding for this work in addition to the global recurrent dotation from university of Poitiers and CHU of Poitiers.